Berinert Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to identification of c1 esterase inhibitor deficiency, approval of plasma derived hae therapies, increased rare disease diagnosis, specialist immunology adoption, emergency airway risk awareness.

The growth in the forecast period can be attributed to improved genetic screening for hae, expansion of rare disease centers, growth in plasma fractionation capacity, better patient access programs, long term safety data availability. Major trends in the forecast period include rising diagnosis of hereditary angioedema, increased use of plasma derived therapies, hospital based acute hae management, focus on rapid on demand treatment, expansion of rare disease awareness programs.

The rising prevalence of genetic disorders is expected to drive the growth of the berinert market in the coming years. Genetic disorders are conditions caused by abnormalities in an individual’s DNA, resulting from mutations in single or multiple genes, chromosomal changes, or a combination of genetic and environmental factors. The increasing prevalence of these disorders is attributed to greater awareness and advances in diagnostic technologies, which enable earlier and more accurate detection of previously undiagnosed conditions. Berinert aids in managing genetic disorders by providing targeted C1 esterase inhibitor therapy, essential for patients with hereditary angioedema caused by C1 inhibitor deficiency. It enhances treatment effectiveness by rapidly controlling acute swelling attacks, improving patient safety, comfort, and overall quality of life. For instance, in July 2025, the National Blood Authority, an Australia-based blood management agency, reported 2,788 patients living with hereditary hemophilia A (HMA) in 2023-2024, up from 2,681 patients in 2022-2023. Therefore, the growing availability of genetic testing is supporting the expansion of the berinert market.

The growing geriatric population is expected to propel the growth of the berinert market. The geriatric population consists of individuals aged 65 years and older, who often experience age-related health, social, and functional changes. This population is increasing due to advancements in healthcare, improved living conditions, better nutrition, and longer life expectancy. Berinert supports the geriatric population by offering effective C1 esterase inhibitor therapy, making it valuable for older adults managing hereditary angioedema and related immune deficiencies. It improves treatment stability by reducing the severity of acute swelling episodes, enhancing patient comfort, safety, and overall quality of life. For example, in July 2024, the UK Parliament's House of Commons Library reported that in 2022, 12.7 million people in the UK were aged 65 or older, representing 19% of the population, with projections indicating this will rise to 22.1 million (27% of the population) by 2072. Therefore, the growing geriatric population is driving the growth of the berinert market.

The rise in healthcare expenditure is expected to further propel the growth of the berinert market. Healthcare expenditure refers to the total spending on healthcare services, including medical treatments, hospital care, medications, and public health initiatives by governments, businesses, and individuals. Rising healthcare spending is driven by the increasing prevalence of chronic diseases, which require long-term and costly management. Higher healthcare expenditure enhances Berinert utilization by improving access to specialized C1 esterase inhibitor therapies, making them more widely available for patients with hereditary angioedema. It also supports better clinical outcomes by enabling investment in advanced treatment options, improving management of acute swelling attacks and overall patient well-being. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms in 2023, compared with 0.9% growth in 2022. Therefore, rising healthcare expenditure is driving the growth of the berinert market.

Major companies operating in the berinert market are CSL Behring.

North America was the largest region in the berinert market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the berinert market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the berinert market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the berinert market by increasing costs associated with plasma collection, fractionation equipment, and biologic processing materials. These effects are most evident in hospital pharmacies and specialty immunology centers across europe and north america. Higher import duties have contributed to increased treatment costs for rare disease therapies. Distribution timelines have also been affected by regulatory and customs procedures. However, tariffs are encouraging regional plasma sourcing and strengthening local biologics manufacturing capabilities.

The berinert market research report is one of a series of new reports that provides berinert market statistics, including berinert industry global market size, regional shares, competitors with a berinert market share, detailed berinert market segments, market trends and opportunities, and any further data you may need to thrive in the berinert industry. This berinert market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Berinert is a prescription medication containing C1 esterase inhibitor (human), a protein derived from human plasma. It is primarily used to treat hereditary angioedema (HAE), a rare genetic disorder characterized by severe swelling episodes in areas such as the face, hands, feet, abdomen, or airway. Berinert replaces the deficient or dysfunctional C1 esterase inhibitor protein in HAE patients, helping regulate the complement and contact systems involved in inflammation and blood vessel permeability.

The primary indications for berinert include hereditary angioedema (HAE) and acquired angioedema (AAE). Hereditary angioedema is a genetic disorder causing severe swelling in the limbs, face, gastrointestinal tract, or airways due to low levels of C1 esterase inhibitor (C1-INH). Berinert is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adults, geriatric, and pediatric patients.

The berinert market consists of sales of C1 esterase inhibitors, infusion pumps, autoinjectors, and prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.